References
Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.
Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004;91:739–46.
Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756–62.
Birnleitner H, Sachet M, Bachleitner-Hofmann T, Oehler R. Immunogenic Effects of FOLFOXIRI Plus Bevacizumab Therapy in Colorectal Peritoneal Carcinomatosis. Paper presented at the 6th Immunotherapy of Cancer Conference (ITOC6) 11–13 April 2019, Vienna.
Franko J, Brahmbhatt R, Tee M, et al. Cellular immunoprofile of peritoneal environment during HIPEC procedure. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08870-3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
ASO Author Reflections offer a brief invited commentary on the article, “Cellular Immunoprofile of Peritoneal Environment During HIPEC Procedure” Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08870-3.
Rights and permissions
About this article
Cite this article
Franko, J., Ferrel, B. & Gorvet, M. ASO Author Reflections: Characterizing the Peritoneal Immune Response to the Surgical and Thermal Trauma of Peritoneal Cytoreduction and HIPEC. Ann Surg Oncol 27, 5014–5015 (2020). https://doi.org/10.1245/s10434-020-08943-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-020-08943-3